Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
66.69
+0.10 (+0.15%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
...
25
26
27
28
29
30
31
32
33
...
47
48
Next >
CHMP Adopts Positive Opinion Recommending Veklury® (Remdesivir) Receive Full Marketing Authorization for the Treatment of Patients With COVID-19
July 22, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic
July 21, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
7 Best Pharmaceutical Stocks to Buy Now
July 20, 2022
These investments represent the best pharmaceutical stocks. Each offers incredible upside potential in the post-pandemic world.
Via
InvestorPlace
European Commission Signs COVID-19 Drug Procurement Deal With Gilead
July 19, 2022
Via
Benzinga
Daily Stock Analysis: Gilead Sciences, Inc.
July 18, 2022
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C.
Via
Talk Markets
Expert Ratings for Gilead Sciences
July 13, 2022
Analysts have provided the following ratings for Gilead Sciences (NASDAQ:GILD) within the last quarter:
Via
Benzinga
Gilead Sciences Contributes Additional $85 Million to Its Foundation to Advance Health Equity
July 20, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury® (Remdesivir)
July 19, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
July 15, 2022
The group has several commonalities, including strong ratings and promising charts.
Via
Investor's Business Daily
Gilead Sciences Whale Trades For July 14
July 14, 2022
Someone with a lot of money to spend has taken a bearish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the big position showed up on publicly...
Via
Benzinga
Why NuCana Shares Are Rising Today?
July 11, 2022
Via
Benzinga
HC Wainwright Finds 'Synergies In Treatment' For This Bipolar-Focused Stock
July 01, 2022
Via
Benzinga
Recent Stock Purchase June 2022
June 27, 2022
I make a stock purchase every single month no matter what is going on in the world and despite the doom and gloom headlines.
Via
Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
July 14, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
$100 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
July 13, 2022
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 7.03% on an annualized basis producing an average annual return of 15.0%. Currently, Gilead Sciences has a market...
Via
Benzinga
Gilead Sciences to Release Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
July 12, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Is Merck & Co. Inc. (NYSE: MRK) a Great Long-Term Dividend Pick?
July 12, 2022
When you're on the hunt for a great long-term dividend stock, you may want the perfect stock. The Dividend Aristocrats or Dividend Kings may come to mind first — companies that have proven they offer a...
Via
MarketBeat
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022
July 13, 2022
Upgrades
Via
Benzinga
Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel
July 12, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Liposome Drug Delivery Market Size, Share, Key Players Analysis, Growth Factors, New Technology, Application and Regional Forecast to 2028
July 08, 2022
Global Liposome Drug Delivery Market Size was estimated at USD 3316.64 million in 2021 and is projected to reach USD 7768.01 million by 2028, exhibiting a CAGR of 12.93% during the forecast period
Via
SBWire
Biotech Stocks To Watch And Pharma Industry News
July 08, 2022
Track the latest trends and leading stocks in the biotech and pharmaceutical industries.
Via
Investor's Business Daily
7 Best Biotech Stocks to Buy in July 2022
July 08, 2022
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict.
Via
InvestorPlace
Biotechs Say ESG Is Core To Their Mission; Do Investors Believe Them?
July 07, 2022
The biotech industry is trying to catch the ESG investing bug. But that doesn't mean investors are giving it credit, executives say.
Via
Investor's Business Daily
Q2 Earnings: Energy and What Else?
July 06, 2022
S&P 500 earnings are expected to be up 2.5% year-over-year on 10.8% higher revenues. But much of that is attributed to energy, which is expected to have another record quarter.
Via
Talk Markets
AstraZeneca's COVID-19 Treatment Allowed In China's Southern City: Reuters
July 06, 2022
Via
Benzinga
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
July 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
$1000 Invested In Gilead Sciences 15 Years Ago Would Be Worth This Much Today
June 28, 2022
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 15 years by 1.74% on an annualized basis producing an average annual return of 8.04%. Currently, Gilead Sciences has a market...
Via
Benzinga
The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives
June 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Kite’s CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma
June 28, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Again Seeks HIV Drug Approval From FDA After Addressing Vial Compatibility Issues
June 27, 2022
Gilead Sciences (NASDAQ: GILD) resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the...
Via
Benzinga
< Previous
1
2
...
25
26
27
28
29
30
31
32
33
...
47
48
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.